bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
bioAffinity Technologies entered a distribution agreement with AvMEDICAL to market its CyPath Lung test to federal healthcare agencies, including the U.S. Department of Veterans Affairs. The partnership leverages AvMEDICAL's status as a Service-Disabled Veteran-Owned Small Business to access established government procurement channels and IDIQ contracts.
Key figures
- Accuracy
- 88%
- Sensitivity
- 92%
- Specificity
- 87%
- Negative predictive value
- 99%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.